Evidence map›Paper›PMID 23360377›Full record

ArticleHuman gene therapy methods2013

Vector production in an academic environment: a tool to assess production costs.

Aaron Boeke, Patrick Doumas, Lilith Reeves, Kyle McClurg, Daniela Bischof, Lina Sego, Alisha Auberry, Mohan Tatikonda, Kenneth Cornetta

Abstract read
In one paragraph

Article in Human gene therapy methods, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aaron BoekeKelley School of Business, Indiana University, Indianapolis, IN 46202, USA.
Patrick Doumas
Lilith Reeves
Kyle McClurg
Daniela Bischof
Lina Sego
Alisha Auberry
Mohan Tatikonda
Kenneth Cornetta

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Indiana Clinical and Translational Science Institute (UL1)UL1TR000006 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2012 to 2013
$5.6M
National Gene Vector Biorepository and Coordinating Center at Indiana UniversityP40HL116242 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI CORNETTA, KENNETH · 2012 to 2017
$5.5M
NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1 TR001108NHLBI NIH HHS P40HL11621NHLBI NIH HHS P40 HL116242PHS HHS HHSN2680001
6 · The paper itself

Abstract

Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.

Indexed as

Cost-Benefit AnalysisData CollectionGenetic TherapyGenetic VectorsRetroviridae

Identifiers

PMID23360377
PMCPMC4015083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.